Since obesity and diabetes are also associated with an excessive inflammatory response (Liu et al., 2015), celastrol acts as a leptin sensitizer in the pharmacological treatment of obesity. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.